Collegium Pharmaceutical, Inc. provided earnings guidance for the year of 2023. For the year, the company expected product revenues, net are expected in the range of $565.0 million to $580.0 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
31.95 USD | +0.53% | +0.92% | +3.80% |
07-01 | Collegium Pharmaceutical, Inc.(NasdaqGS:COLL) added to Russell 2000 Growth-Defensive Index | CI |
07-01 | Collegium Pharmaceutical, Inc.(NasdaqGS:COLL) added to Russell 2000 Defensive Index | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+3.80% | 1.04B | |
+61.53% | 856B | |
+38.95% | 631B | |
-3.66% | 359B | |
+15.06% | 325B | |
+9.18% | 297B | |
+5.89% | 234B | |
+16.53% | 226B | |
+15.67% | 177B | |
+2.47% | 165B |
- Stock Market
- Equities
- COLL Stock
- News Collegium Pharmaceutical, Inc.
- Collegium Pharmaceutical, Inc. Provides Earnings Guidance for the Year of 2023